Trial Profile

24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acamprosate/baclofen (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Therapeutic Use
Acronyms PLEODIAL-II
Sponsors Pharnext

Most Recent Events

20 Jul 2017 Results from PLEODIAL clinical trial (this study and NCT02361424), presented at the Alzheimer's Association International Conference 2017
13 Dec 2016 Results published in the Pharnext Media Release.
13 Dec 2016 According to a Pharnext media release, data from PLEODIAL clinical trial (this study and CTP 253068) presented at the 9th Clinical Trials on Alzheime's Disease (CTAD) conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com